SIV-Specific Antibodies are Elicited by a Recombinant Fowlpox Virus Co-expressing SIV Gag and envT

[1]  I. Wilson,et al.  Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer. , 2015, Acta crystallographica. Section D, Biological crystallography.

[2]  A. Fauci,et al.  Toward an HIV vaccine: A scientific journey , 2015, Science.

[3]  H. Schuitemaker,et al.  Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys , 2015, Science.

[4]  Xiao Li,et al.  Construction and characterization of novel fowlpox virus shuttle vectors. , 2015, Virus research.

[5]  N. Michael,et al.  Accelerating HIV-1 Vaccine Efficacy Trials , 2014, Cell.

[6]  William R Schief,et al.  Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5 , 2014, Proteins.

[7]  A. Fauci,et al.  Ending AIDS--is an HIV vaccine necessary? , 2014, The New England journal of medicine.

[8]  D. Barouch.  The quest for an HIV-1 vaccine--moving forward. , 2013, The New England journal of medicine.

[9]  Zhiwei Chen,et al.  The potential of the human immune system to develop broadly neutralizing HIV-1 antibodies: implications for vaccine development , 2013, AIDS.

[10]  I. Berkower,et al.  Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques , 2013, Retrovirology.

[11]  S. Reed,et al.  HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. , 2013, Vaccine.

[12]  R. Sanders,et al.  Broadly neutralizing antibodies against HIV-1: templates for a vaccine. , 2013, Virology.

[13]  Jessica B. Graham.  Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial , 2012 .

[14]  D. Barouch,et al.  Accelerated Heterologous Adenovirus Prime-Boost SIV Vaccine in Neonatal Rhesus Monkeys , 2012, Journal of Virology.

[15]  C. Morrison,et al.  Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients , 2012, Proceedings of the National Academy of Sciences.

[16]  Felipe García,et al.  Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). , 2011, Vaccine.

[17]  M. Maciel,et al.  Mucosal and systemic anti-GAG immunity induced by neonatal immunization with HIV LAMP/gag DNA vaccine in mice. , 2011, Immunobiology.

[18]  D. Montefiori,et al.  Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. , 2011, Virology.

[19]  K. Ruxrungtham,et al.  An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection , 2010, Human vaccines.

[20]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[21]  J. Gulley,et al.  A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). , 2006, Clinical breast cancer.

[22]  F. Falkner,et al.  Role of the fowlpox virus thymidine kinase genefor the growth of FPV recombinants in cell culture , 1997, Archives of Virology.